Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).

Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Ráčil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MÁ, Rodríguez JY, Desoubeaux G, Barać A, García-Vidal C, Hoenigl M, Mehta SR, Cheng MP, Klyasova G, Heinz WJ, Iqbal N, Krause R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGT; FungiScope® ECMM/ISHAM Working Group .

J Antimicrob Chemother. 2019 Aug 8. pii: dkz344. doi: 10.1093/jac/dkz344. [Epub ahead of print]

PMID:
31393591
2.
3.

The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.

Bagshaw E, Kuessner D, Posthumus J, Escrig C, Blackney M, Heimann SM, Cornely OA.

Future Microbiol. 2017 May;12:515-525. doi: 10.2217/fmb-2016-0231. Epub 2017 Feb 13.

4.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Tiphine M, Letscher-Bru V, Herbrecht R.

Transpl Infect Dis. 1999 Dec;1(4):273-83. Review.

PMID:
11428998
5.

Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.

Heimann SM, Vehreschild MJGT, Cornely OA, Heinz WJ, Grüner B, Silling G, Kessel J, Seidel D, Vehreschild JJ.

J Hosp Infect. 2019 Mar;101(3):339-346. doi: 10.1016/j.jhin.2018.11.003. Epub 2018 Nov 10.

PMID:
30423409
6.

Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.

Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II.

Cancer. 2008 Mar 15;112(6):1282-7. doi: 10.1002/cncr.23311.

7.

Lipid formulations of amphotericin B as first-line treatment of zygomycosis.

Petrikkos GL.

Clin Microbiol Infect. 2009 Oct;15 Suppl 5:87-92. doi: 10.1111/j.1469-0691.2009.02987.x. Review.

8.

Amphotericin B formulations: a comparative review of efficacy and toxicity.

Hamill RJ.

Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. Review.

PMID:
23729001
9.
10.

Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports.

Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SC, Kong DCM.

Int J Antimicrob Agents. 2019 May;53(5):589-597. doi: 10.1016/j.ijantimicag.2019.01.002. Epub 2019 Jan 10.

PMID:
30639526
11.

Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Lewis RE, Albert ND, Kontoyiannis DP.

Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.

12.

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.

Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, Herbrecht R, Wolff M, Ribaud P, Lortholary O; French Mycosis Study Group.

J Antimicrob Chemother. 2015 Nov;70(11):3116-23. doi: 10.1093/jac/dkv236. Epub 2015 Aug 27.

PMID:
26316385
13.

Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.

Heimann SM, Penack O, Heinz WJ, Rachow T, Egerer G, Kessel J, Claßen AY, Vehreschild JJ.

Int J Infect Dis. 2019 Jun;83:130-138. doi: 10.1016/j.ijid.2019.04.006. Epub 2019 Apr 9.

14.

Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.

Mezhir JJ, Mullane KM, Zarling J, Satoskar R, Pai RK, Roggin KK.

Surg Infect (Larchmt). 2009 Oct;10(5):447-51. doi: 10.1089/sur.2008.049. Review.

PMID:
19485785
15.

Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups.

Campbell RS, Chaudhari P, Hays HD, Taylor RJ, Nathanson BH, Bozzette SA, Horn DL.

Clinicoecon Outcomes Res. 2013 Oct 24;5:507-17. doi: 10.2147/CEOR.S46834. eCollection 2013.

17.

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.

Camargo JF, Yakoub D, Cho-Vega JH.

Mycopathologia. 2015 Oct;180(3-4):187-92. doi: 10.1007/s11046-015-9914-1. Epub 2015 Jun 26.

PMID:
26112998
18.

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.

Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomics. 2004;22(5):301-10.

PMID:
15061680
19.

COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW.

Grazziotin LR, Moreira LB, Ferreira MAP.

Int J Technol Assess Health Care. 2018 Jan;34(3):343-351. doi: 10.1017/S026646231800034X. Epub 2018 Jun 13. Review.

PMID:
29897025
20.

Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.

Mihara T, Kakeya H, Izumikawa K, Obata Y, Nishino T, Takazono T, Kosai K, Morinaga Y, Kurihara S, Nakamura S, Imamura Y, Miyazaki T, Tsukamoto M, Yamamoto Y, Yanagihara K, Tashiro T, Kohno S.

J Infect Chemother. 2014 Feb;20(2):104-8. doi: 10.1016/j.jiac.2013.09.002. Epub 2013 Dec 11.

PMID:
24462443

Supplemental Content

Support Center